160 related articles for article (PubMed ID: 32178572)
1.
Wang J; Fan J; Gao W; Wu Y; Zhao Q; Chen B; Ding Y; Wen S; Nan X; Wang B
Stem Cells Dev; 2020 Jun; 29(12):774-785. PubMed ID: 32178572
[TBL] [Abstract][Full Text] [Related]
2. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation.
Li R; Chen S; Zhan J; Li X; Liu W; Sheng X; Lu Z; Zhong R; Chen L; Luo X; Hu Y; Ouyang Y; Liu T; Zhang Q; Zhang S
Cell Death Dis; 2020 Jan; 11(1):41. PubMed ID: 31959918
[TBL] [Abstract][Full Text] [Related]
4. α2δ1 may be a potential marker for cancer stem cell in laryngeal squamous cell carcinoma.
Huang C; Li Y; Zhao W; Zhang A; Lu C; Wang Z; Liu L
Cancer Biomark; 2019; 24(1):97-107. PubMed ID: 30475757
[TBL] [Abstract][Full Text] [Related]
5. PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics.
Sheng X; Li Y; Li Y; Liu W; Lu Z; Zhan J; Xu M; Chen L; Luo X; Cai G; Zhang S
BMC Cancer; 2019 Aug; 19(1):840. PubMed ID: 31455288
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells.
Liu J; Tang Q; Li S; Yang X
Oncotarget; 2016 Dec; 7(52):86446-86456. PubMed ID: 27880721
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
[TBL] [Abstract][Full Text] [Related]
8. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.
Yang JP; Liu Y; Zhong W; Yu D; Wen LJ; Jin CS
Chin Med J (Engl); 2011 Apr; 124(7):1055-60. PubMed ID: 21542968
[TBL] [Abstract][Full Text] [Related]
9. CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma.
Fukusumi T; Ishii H; Konno M; Yasui T; Nakahara S; Takenaka Y; Yamamoto Y; Nishikawa S; Kano Y; Ogawa H; Hasegawa S; Hamabe A; Haraguchi N; Doki Y; Mori M; Inohara H
Br J Cancer; 2014 Jul; 111(3):506-14. PubMed ID: 24874475
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cancer stem cell properties of a mitotically quiescent subpopulation of p75NTR-positive cells in esophageal squamous cell carcinoma.
Kojima H; Okumura T; Yamaguchi T; Miwa T; Shimada Y; Nagata T
Int J Oncol; 2017 Jul; 51(1):49-62. PubMed ID: 28534989
[TBL] [Abstract][Full Text] [Related]
12. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma.
Liu S; Qin Z; Mao Y; Wang N; Zhang W; Wang Y; Chen Y; Jia L; Peng X
Theranostics; 2024; 14(2):622-639. PubMed ID: 38169606
[No Abstract] [Full Text] [Related]
14. Ly6D facilitates chemoresistance in laryngeal squamous cell carcinoma through miR-509/β-catenin signaling pathway.
Wang J; Sheng N; Li Y; Fan Y; Nan X; Fu R
Am J Cancer Res; 2023; 13(5):2155-2171. PubMed ID: 37293155
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma.
Bae WJ; Koo BS; Lee SH; Kim JM; Rho YS; Lim JY; Moon JH; Cho JH; Lim YC
Br J Cancer; 2017 Dec; 117(12):1810-1818. PubMed ID: 29096401
[TBL] [Abstract][Full Text] [Related]
16. Targeting BMI1
Chen D; Wu M; Li Y; Chang I; Yuan Q; Ekimyan-Salvo M; Deng P; Yu B; Yu Y; Dong J; Szymanski JM; Ramadoss S; Li J; Wang CY
Cell Stem Cell; 2017 May; 20(5):621-634.e6. PubMed ID: 28285905
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
18. Expression profile of stem cell markers and ABC transporters in 5-fluorouracil resistant Hep-2 cells.
Duz MB; Karatas OF
Mol Biol Rep; 2020 Jul; 47(7):5431-5438. PubMed ID: 32627138
[TBL] [Abstract][Full Text] [Related]
19. Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.
Sim MW; Grogan PT; Subramanian C; Bradford CR; Carey TE; Forrest ML; Prince ME; Cohen MS
Laryngoscope; 2016 May; 126(5):E184-90. PubMed ID: 26690734
[TBL] [Abstract][Full Text] [Related]
20. Matrix stiffness regulates the proliferation, stemness and chemoresistance of laryngeal squamous cancer cells.
Hui L; Zhang J; Ding X; Guo X; Jiang X
Int J Oncol; 2017 Apr; 50(4):1439-1447. PubMed ID: 28259905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
